Methotrexate serum binding in rheumatoid arthritis.
The serum binding of methotrexate was determined by equilibrium dialysis using radiolabelled methotrexate. Methotrexate was only albumin-bound in serum. The binding was 46% in controls versus 42% in rheumatoid arthritis and 44% in cancer. Serum binding was significantly decreased by salicylate and high concentration of naproxen. Hypoalbuminemia and concomitant administration of salicylate or naproxen may influence methotrexate toxicity.
Claudepierre
P
P
Laboratoire de Pharmacologie, Faculté de Médecine, Créteil, Université Paris, France.
Urien
S
S
Chevalier
X
X
Chassany
O
O
Larget-Piet
B
B
Tillement
J P
JP
D001172:Arthritis, Rheumatoid / Q000097:blood*; D001798:Blood Proteins / Q000378:metabolism*; D003956:Dialysis; D006801:Humans; D008727:Methotrexate / Q000378:metabolism*; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism; D014316:Tritium
D001798:Blood Proteins; D012709:Serum Albumin; D014316:Tritium; D008727:Methotrexate